APA (7th ed.) Citation

de Velasco, G., Eigentler, T., Isambert, N., Mouton, J., Robert, C., Schusterbauer, C. M., & Vijayakumar, J. (2023). OMNIA-1: A phase I/II study, an IL-2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti-PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma. Journal of clinical oncology, 41(16_suppl), TPS9599. https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS9599

Chicago Style (17th ed.) Citation

de Velasco, Guillermo, Thomas Eigentler, Nicolas Isambert, Julie Mouton, Caroline Robert, Claudia Michaela Schusterbauer, and Jayanthi Vijayakumar. "OMNIA-1: A Phase I/II Study, an IL-2R-βγ Targeted Antibody-IL-2 Fusion Protein, as Monotherapy or in Combination with Anti-PD-1 or Anti-CTLA-4 Antibodies, in Patients with Advanced Melanoma." Journal of Clinical Oncology 41, no. 16_suppl (2023): TPS9599. https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS9599.

MLA (9th ed.) Citation

de Velasco, Guillermo, et al. "OMNIA-1: A Phase I/II Study, an IL-2R-βγ Targeted Antibody-IL-2 Fusion Protein, as Monotherapy or in Combination with Anti-PD-1 or Anti-CTLA-4 Antibodies, in Patients with Advanced Melanoma." Journal of Clinical Oncology, vol. 41, no. 16_suppl, 2023, p. TPS9599, https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS9599.